Disease‐causing variants in ERCC2 can partially inactivate these activities, giving rise to symptoms seen in TTD, Cockayne syndrome (CS) and xeroderma pigmentosa (XP). This evidence concerns the gene ERCC2 and Cockayne syndrome.